Tag Archives: reimbursement

Value-Based Pricing Could Counter Innovation, Says UK Think Tank

By Julian Upton | Published: March 25, 2011
The UK government’s proposals to introduce value-based pricing (VBP) — which aims to create a stronger link between the price the National Health Service pays for a medicine and the value it delivers (and in the process, ostensibly, further incentivize therapeutic innovation) — could actually serve to ‘hinder’ innovation, according to a UK think tank.
Posted in Europe, Global, R&D, pricing | Also tagged , , , , , | Leave a comment

A Fine Line Between Regulation and Evolution

By Julian Upton | Published: December 1, 2010
The strict regulatory divide between market authorization and price reimbursement is crumbling in the US. Ansis Helmanis asks — is industry prepared to adapt or challenge? On September 17, the FDA and CMS jointly issued a Federal Register (FR) notice that they were establishing a process for overlapping evaluations of premarket, FDA-regulated medical products when [...]
Posted in FDA, Market Access, Regulatory | Also tagged , , , | Leave a comment

Wins and Losses from Risk-Sharing Agreements

By William Looney | Published: November 17, 2010
Can you manage the external market impact? Risk-sharing agreements – where companies contract with reimbursement or assessment authorities to guarantee a new drug’s performance, often against specific outcomes measures, in return for access to patients – are among the latest innovations in managing health care costs. Use of the tool is standard in Australia, is [...]
Posted in Europe, Global, Regulatory, Strategy, healthcare, pricing | Also tagged , , , , , | Leave a comment